Peli BioThermal has acquired Evo Cold Chain, enhancing its cryogenic transport capabilities in the cell and gene therapy logistics market. The $93 billion global market demands reliable temperature-controlled solutions, driving strategic consolidation in the industry. The acquisition complements Peli’s existing packaging systems, positioning them to serve more segments of the life sciences supply chain. Platinum Equity’s involvement reflects growing investor interest in cold chain logistics providers capable of handling technical challenges. The acquisition highlights the trend of larger logistics players absorbing specialized companies to balance scale and niche knowledge. Peli BioThermal’s move positions them as a leader in the fast-growing logistics market for cell and gene therapies, emphasizing the importance of stable cold chain infrastructure. Logistics companies are adapting to industries with zero tolerance for errors, raising the bar for precision, temperature control, and chain-of-custody documentation. The acquisition could establish Peli as an end-to-end cold chain logistics provider for next-generation medicine, signaling the cold chain as the next frontier for growth and competitive advantage.

Read more at Yahoo Finance: Peli BioThermal expands cold chain capabilities with EVO acquisition